Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

phase icon View trials
by phase
cancer type icon View trials by
cancer type
target icon View trials by
therapeutic target

Early Development

BRUIN; NCT03740529
BTK Inhibitor Enrolling
Advanced Solid Tumors
CD73 Inhibitor Enrolling
Pediatric Cancer
CDK4 & 6 Inhibitor Enrolling
Advanced Hematologic Malignancies
IDH1 Inhibitor Enrolling
Advanced Solid Tumors
IDH1 Inhibitor Enrolling
LIBRETTO-001; NCT03157128
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
RET Inhibitor Enrolling
LIBRETTO-121; NCT03899792
Pediatric Cancer
RET Inhibitor Enrolling
Advanced Solid Tumors
VEGF Receptor-2 Antagonist Enrolling
Gastric Cancer, Hepatocellular Carcinoma, or NSCLC
VEGF Receptor-2 Antagonist
Healthy Volunteers
VEGF Receptor-2 Antagonist Enrolling

Gastrointestinal Cancer

Gynecologic Cancer

EMBER; NCT04188548
Breast Cancer or Endometrial Cancer
Selective ER Degrader Enrolling

Neurologic Cancer

Thyroid Cancer

LIBRETTO-531; NCT04211337
Medullary Thyroid Cancer
RET Inhibitor Enrolling

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.